Blog

FDA approves the targeted therapy adagrasib for people with advanced colorectal cancer – MSKCC

Photo of Rona Yaeger from MSKCC/LinkedIn

Jun 27, 2024, 11:18

FDA approves the targeted therapy adagrasib for people with advanced colorectal cancer – MSKCC

Memorial Sloan Kettering Cancer Center shared a post on LinkedIn:

“The US Food and Drug Administration has approved the targeted therapy adagrasib in combination with another targeted therapy for people with advanced colorectal cancer caused by a gene mutation called KRAS-G12C. Dr. Rona Yaeger, a gastrointestinal oncologist at Memorial Sloan Kettering Cancer Center (MSK), led the trial that resulted in this approval.

“Since we started this trial, I have had people coming to me from all over to receive this treatment,” Dr. Yaeger says. “Now that this drug combination is approved, many more patients will be able to benefit.”

Learn more here.”

Source: Memorial Sloan Kettering Cancer Center/LinkedIn

“The US Food and Drug Administration Adagrasib cancer colorectal cancer FDA KRAS G12C Memorial Sloan Kettering Cancer Center MSK MSKCC OncoDaily Oncology Rona Yaeger

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage